20/20 GeneSystems
Diagnostic Testing for COVID-19 & Cancer
Overview
Raised: $2,903,017
Rolling Commitments ($USD)
06/30/2021
$5,416
2,815
2000
Healthcare & Pharmaceuticals
HealthTech
B2B/B2C
Medium
High
Balance Sheet
Cash and Cash Equivalents |
$636,018 |
Investment Securities |
$1,647,806 |
Accounts and Notes Receivable |
$32,498 |
Property, Plant and Equipment (PP&E) |
$48,924 |
Total Assets |
$3,125,886 |
Accounts Payable & Accrued Liabilities |
$898,785 |
Long Term Debt |
$0 |
Total Liabilities |
$976,560 |
Total Stockholders' Equity |
$2,149,326 |
Total Liabilities and Equity |
$3,125,886 |
Statement of Comprehensive Income Information
Total Revenues |
$288,300 |
Costs & Expenses Applicable to Rev |
$263,917 |
Depreciation and Amortization |
$23,550 |
Net Income |
$-2,425,338 |
Earnings Per Share - Basic |
$-0.51 |
Earnings Per Share - Diluted |
$-0.51 |
Raise History
Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|---|
20/20 GeneSystems | 12/21/2022 | StartEngine | $58,400,000 | $232,704 | Convertible Note | Funded | RegCF |
20/20 GeneSystems | 06/27/2021 | StartEngine | $38,500,000 | $2,903,017 | Equity - Preferred | Funded | RegA+ |
20/20 GeneSystems | 11/01/2020 | SeedInvest | $38,500,000 | $3,792,229 | Equity - Preferred | Funded | RegA+ |
20/20 GeneSystems | 12/14/2017 | Microventures | $23,000,000 | $1,064,807 | Equity - Preferred | Funded | RegCF |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual